/Companies

Labgeniustx

London · Founded 2012 · 18 known investors

Find your way into Labgeniustx

Sign up to see every warm intro you have to Labgeniustx

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Labgeniustx team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

LabGenius develops EVA, an automated antibody discovery platform that uses machine learning and automation to identify and co-optimize complex therapeutic antibodies such as multispecifics. Its internal pipeline focuses on selectivity-enhanced antibodies for treating solid tumours.

Founders & leadership

HR
Harrison RickerbyNamed on SEC filing

Board

JFJames Field
James FieldFounderFounder at Octopus Ventures

Investors · 18

Atomicolisted by AtomicoLondon

How we know: a partner's Signal profile · funding news · labgeniustx.com · atomico.com · Not right? Tell us

M Ventureslisted by M VenturesAmsterdam · $10.8M

How we know: M Ventures's portfolio page · labgeniustx.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

System.Onereported

How we know: funding news · Not right? Tell us

Also in the syndicate · 1

LG Corp

Funding

SEC filings, press & company announcements

$2.8M disclosed across 1 of 3 rounds · 2017–2024

▶$2.8MraisedOct 2017 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James FieldExecutive Officer, Director
  • Harrison RickerbyExecutive Officer, Director
Offering amount
$2.8M
Amount sold
$2.8M
First sale
Oct 2017
Incorporated
Corporation, United Kingdom
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Frequently asked questions

What does Labgeniustx do?
LabGenius develops EVA, an automated antibody discovery platform that uses machine learning and automation to identify and co-optimize complex therapeutic antibodies such as multispecifics. Its internal pipeline focuses on selectivity-enhanced antibodies for treating solid tumours.
Who are Labgeniustx's investors?
Labgeniustx's investors include Acequia Capital (AceCap), Air Street Capital, Atomico, Backed, Beast Ventures, Champion Hill Ventures, Gaingels, Gigafund and 9 more.
How much funding has Labgeniustx raised?
Labgeniustx has disclosed $2.8M raised across 1 of its 3 known rounds.
Where is Labgeniustx headquartered?
Labgeniustx is headquartered in London.